Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Blogs » ED Push » Prochlorperazine Combo Better Than Opioid Migraine Relief in ED

    ED Push
    ED Push RSS FeedRSS

    edpush-webheader-rm

    Free Monthly News from the Award Winning Publisher of:

    • Emergency Medicine Reports
    • Trauma Reports
    • Critical Care Alert
    • ED Management
    • ED Legal Letter
    • Pediatric Emergency Medicine Reports
    • EM Reports' Study Guide 2018
    • STROKE: The Cutting Edge: 2017
    • Pediatric Trauma 2018
    • STEMI Watch 2018
     

     

    Prochlorperazine Combo Better Than Opioid Migraine Relief in ED

    November 2, 2017
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share
    By Brenda Mooney

    The opioid hydromorphone often is used as first-line treatment for migraine in the emergency department (ED). A new study calls that practice into question, however, suggesting that a better alternative exists.

    The study published in the journal Neurology determined that the dopamine antagonist prochlorperazine — given in conjunction with diphenhydramine to prevent restlessness, a common side effect — is more effective than hydromorphone.

    Prochlorperazine administered intravenously blocks the release of dopamine, helping to relieve the headaches.

    "People go to U.S. emergency departments 1.2 million times a year with migraine, and the opioid drug hydromorphone is used in 25 percent of these visits, yet there have been no randomized, high-quality studies on its use for acute migraine," explained study author Benjamin W. Friedman, MD, MS, of Albert Einstein College of Medicine in the Bronx, N.Y.

    The study also explored whether the use of an opioid drug could lead to addiction and return ED visits.

    “While this study demonstrates the overwhelming superiority of prochlorperazine over hydromorphone for initial treatment of acute migraine, the results do not suggest that treatment with IV opioids leads to long-term addiction,” Friedman said. “In addition, the results should not be used to avoid the use of opioids for people who have not responded well to anti-dopaminergic drugs.”

    For the study, researchers focused on 127 patients presenting to New York state EDs with migraine. To determine the rate of sustained headache relief after 48 hours, half of the participants were given hydromorphone, while the other half received prochlorperazine.

    The study was ended with just 127 participants because 48-hour results showed that prochlorperazine was significantly superior to hydromorphone. The original endpoint was sustained headache relief after 48 hours, defined as having a mild headache or no headache two hours after receiving the drug and maintaining that level for 48 hours without requiring a rescue medication.

    Results indicate that, by the 48-hour point, 60% of patients administered prochlorperazine had sustained headache relief, compared to 31% of those receiving hydromorphone. In fact, 31% of those given hydromorphone sought a second dose of the drug, compared to just 8% of those who received prochlorperazine. In addition, 36% of the hydromorphone group requested other pain-reliever drugs, compared to 6% of the prochlorperazine group.



    EMTALA & The On-Call Physician

    This webinar covers EMTALA regulations concerning on-call physicians to help hospitals comply with the federal law and guarantee uninterrupted reimbursements. Our expert, Sue Dill Calloway, RN, MSN, JD, also discusses The Patient Protection and Affordable Care Act’s specific provisions related to insurers and EMTALA-covered patients.

    Download Now - red


     

    newsletter-sponsors-relias_sr

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    ED Push

    View PDF
    ED Push - November 2017 Issue
    November 1, 2017

    Table Of Contents

    EDs Play an Increasingly Outsized Role in Providing US Healthcare

    Prochlorperazine Combo Better Than Opioid Migraine Relief in ED

    One in Five Public ED Patients Visited Another Facility for Same Complaint

    Factors Keeping Older Patients From Presenting to ED With AMI

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2021 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing